A Phase 2b / 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis

  • Kerr, Peter (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA/ERM Reference Number: 90646
SSA Reference: SSA/90646/MonH-2023-375908(v1)
Monash Health Reference: RES-23-0000-422X
StatusActive
Effective start/end date13/07/23 → 13/07/28